| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 217.3 | 167.1 | 123.5 |
| Other income | 1.8 | 2.8 | 1.0 |
| Total income | 219.1 | 169.8 | 124.5 |
| Profit before exceptional items & tax | 28.9 | 22.4 | 13.7 |
| Exceptional items | 0.0 | -1.3 | 0.0 |
| Profit before tax | 28.9 | 21.1 | 13.7 |
| Net profit | 21.5 | 16.0 | 9.9 |
| Operating margin | 13.2% | 12.4% | 11.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +117.20% |
|---|---|
| Net profit, quarter on quarter | +34.40% |
| Revenue, year on year | +76.00% |
| Operating profit, year on year | +113.40% |
| Operating profit, quarter on quarter | +38.30% |
NSE results filing, NSE: TATVA. Figures extracted from the filing.
Tatva Chintan Pharma Chem Ltd: key numbers
- Share price
- ₹1,634.90
- Market cap
- ₹3,824 Cr
- Revenue (annual)
- ₹505.9 Cr
- Net profit (annual)
- ₹42.05 Cr
- P/E (TTM)
- 60.8×Sector 34.5×
- Promoter holding
- 72.02%+0.00% QoQ
- FII holding
- 4.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tatva Chintan Pharma Chem Ltd
All →Tatva Chintan Pharma Chem Investor Presentation: Key Takeaways
Tatva Chintan reported record quarterly revenue of ₹2,173 Mn for Q2 FY27, up 76% YoY, driven by strong SDA demand. EBITDA margins remained flat at 19% due to high solvent costs and freight spikes.
Tatva Chintan Pharma Chem Other Announcement
The company has filed its quarterly shareholding pattern as per SEBI regulations. This routine disclosure provides details on the current shareholding structure.
Tatva Chintan Pharma Chem Board Meeting Date
Tatva Chintan Pharma Chem has scheduled a Board meeting for 19 October 2026 to consider Q1 FY27 financial results. The trading window will remain closed until 48 hours after results are published.
Tatva Chintan Pharma Chem Annual General Meeting
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
Tatva Chintan Pharma Chem Credit Rating
CRISIL Ratings upgraded Tatva Chintan's long-term bank facilities to CRISIL A-/Stable and short-term facilities to CRISIL A2+. This upgrade reflects the company's improved credit profile.
Tatva Chintan Pharma Chem Business Update
Tatva Chintan Pharma Chem Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report highlights its specialty chemicals operations and ESG metrics.